Board of Directors
Learn about our Board of Directors and the experience that they bring to Hemanext.
Andrew Dunham, PhD
Chief Executive Officer- Hemanext
Andrew Dunham, who has been an integral part of the company’s success story, serves as the Chief Executive Officer. Dr. Dunham joined Hemanext in 2015 as VP of Clinical & Scientific Affairs and, over the past eight years, played a key role in developing a scientific platform to characterize the biological and biochemical differences between hypoxic and conventional RBCs. His contributions not only led to securing an NIH grant for a pivotal clinical study but also, in collaboration with co-authors, earned the prestigious Association for the Advancement of Blood and Biotherapies (AABB) RISE Award for impeccable study design, innovation, significance, and effective communication. As a scientist, he has authored or co-authored thirty-two publications with hundreds of citations, and on the business front, his distinguished fourteen-year tenure at Baxter Healthcare culminated in five years as the global Vice President of Research and Development, where he led a multinational team of several hundred professionals.
Classic Communities Organization CEO
Director and Owner of Empresas Indumotora SA
Former Vice Chairman and Chief Investment Officer, T. Rowe Price
American Enterprise Institute Resident Fellow
Paul M. Ness, M.D.
Senior Director of the Transfusion Medicine Division and Professor of Pathology, Medicine, and Oncology at the Johns Hopkins University School of Medicine
Dr. Ness served as Division Director from 1979-2018. From 1983-2000 he directed the Baltimore division of American Red Cross Blood Services leading the Baltimore community through the transfusion issues with the AIDS epidemic. At Johns Hopkins he helped to develop programs in patient blood management, bloodless medicine, therapeutic apheresis, and advanced immunohematology. Prior to coming to Hopkins, he was an undergraduate at MIT, a medical student at SUNY Buffalo, a medical resident at Hopkins, a staff associate in the blood program at NIH, and a hematology –transfusion medicine fellow at UC San Francisco
Dr. Ness was a member of the AABB Board of Directors for many years and became President in 1999. He served as editor of Transfusion from 2003-2018. Dr. Ness has written over 250 articles for medical journals and three texts. Dr. Ness also has extensive experience in transfusion related research with emphasis upon transfusion complications including transfusion transmitted infections and immune destruction of transfused cells. He was a member of the FDA Blood Products Advisory Committee and is currently a member of the Health and Human Services Advisory Committee of Blood and Tissue Safety and Availability.
He served as PI for the Johns Hopkins site of the Transfusion Medicine Hemostasis Clinical Trial Network, funded by NHLBI. Dr. Ness was co-PI for a project funded by the NHLBI REDS III program to study donor virus epidemiology and blood utilization issues in China. He has served as a consultant to the coordinating centers of REDS II, REDS III, and REDS IV. He continues to serve as a consultant to many companies involved in transfusion medicine supplies and practices.
Former partner in the corporate finance and M&A practice of Latham & Watkins LLP
Ismail Kola, PhD
General Partner at Forepont, Visiting Professor of Medicine at Oxford University and Adjunct Professor at several universities and medical schools in the US, Australia and the UK
Prior to Forepont, Ismail held several senior executive positions in the pharmaceutical industry. He has published 159 papers in top scientific journals which have been cited over 16,000 times and has led teams that have brought numerous major medicines to the market during his 20-year career in the pharmaceutical industry.
Ismail Kola was until 2018 the CSO of UCB, His previous positions were: Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, and Chief Scientific Officer, Schering Plough Corporation; Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid, Merck and Chairman of Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team; and Vice President Research, and Global Head, Genomics and Biotechnology at Pharmacia Corporation.
Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School, and Director of the Research Center for Functional Genomics and Human Disease for 15 years.
He is Chairman of the Board of Directors of Athersys Inc. (ATHX, Nasdaq) and a Director of GPN vaccines (Australia).